104 studies found for:    small cell lung ca | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Conditions: Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small Cell Lung;   Carcinoma, Thymic
Interventions: Drug: AZD6244;   Drug: MK-2206;   Drug: Lapatinib;   Drug: Erlotinib;   Drug: Sunitinib;   Procedure: Molecular Profiling
2 Recruiting Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China
Condition: Carcinoma, Non-Small-Cell Lung
3 Recruiting A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy
Condition: Lung Cancer
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Other: Placebo
4 Recruiting Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer
Condition: Lung Cancer
Interventions: Drug: Nivolumab;   Drug: Topotecan;   Drug: Amrubicin
5 Recruiting Multiple Ascending Dose w/Expansion in Relapsed/Refractory SCLC
Condition: Small Cell Lung Cancer
Intervention: Biological: BMS-986012 (anti-fucosyl-GM1)
6 Not yet recruiting A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy
Conditions: Small Cell Lung Cancer;   Platinum-sensitive
Intervention: Drug: BIBF1120
7 Not yet recruiting Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Pancreatic Adenocarcinoma;   Pancreatic Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Small Cell Lung Carcinoma;   Stage III Pancreatic Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Small Cell Lung Carcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Small Cell Lung Carcinoma;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Small Cell Lung Carcinoma;   Stage IVA Pancreatic Cancer;   Stage IVB Pancreatic Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: 18F-Fluoromisonidazole;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Procedure: Positron Emission Tomography
8 Recruiting Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide
Condition: Small Cell Lung Cancer
Interventions: Other: cytology specimen collection procedure;   Other: laboratory biomarker analysis
9 Recruiting Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy
Condition: Extensive Stage Small Cell Lung Carcinoma
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis
10 Recruiting Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Small Cell Lung Cancer That Has Relapsed or Not Responded to Treatment
Condition: Recurrent Small Cell Lung Carcinoma
Interventions: Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Drug: Topotecan Hydrochloride
11 Recruiting Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy
Condition: Extensive Stage Small Cell Lung Cancer
Intervention: Procedure: bioelectric impedance analysis
12 Recruiting Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
Condition: Recurrent Small Cell Lung Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pegylated Irinotecan;   Other: Pharmacological Study
13 Recruiting Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
Condition: Lung Cancer
Interventions: Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
14 Recruiting Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
Conditions: Adult Solid Neoplasm;   Extensive Stage Small Cell Lung Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Small Cell Lung Carcinoma;   Stage III Pancreatic Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Navitoclax;   Other: Pharmacological Study;   Drug: Trametinib
15 Recruiting Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
Conditions: Limited Stage Small Cell Lung Cancer;   Small Cell Lung Cancer
Interventions: Drug: Ipilimumab;   Drug: Nivolumab
16 Recruiting Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Carcinoma;   Lung Adenocarcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Small Cell Lung Carcinoma;   Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Auranofin;   Drug: Sirolimus;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
17 Recruiting Phase II Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer;   Tumors Metastatic to Brain;   Metastatic Breast Cancer
Interventions: Drug: pegylated irinotecan NKTR 102;   Other: laboratory biomarker analysis
18 Recruiting Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Conditions: Liver Cancer;   Anxiety Disorder;   Depression;   Small Cell Lung Cancer;   Extrahepatic Bile Duct Cancer;   Malignant Mesothelioma;   Pancreatic Cancer;   Esophageal Cancer;   Gastric Cancer;   Non-small Cell Lung Cancer
Intervention: Other: Early palliative care
19 Not yet recruiting Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Conditions: Estrogen Receptor Negative;   Head and Neck Squamous Cell Carcinoma;   HER2/Neu Negative;   Hormone-Resistant Prostate Cancer;   Metastatic Pancreatic Adenocarcinoma;   Progesterone Receptor Negative;   Solid Neoplasm;   Stage III Mesothelioma;   Stage IIIA Gastric Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Small Cell Lung Carcinoma;   Stage IIIB Gastric Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Small Cell Lung Carcinoma;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Mesothelioma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Small Cell Lung Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
20 Recruiting Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors
Condition: Solid Tumor
Interventions: Drug: Ulocuplumab;   Drug: Nivolumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years